Efficacy of a multi-clade inactivated recombinant vaccine against the circulating highly pathogenic influenza A/H5N1 of clade 2.3.4.4b in poultry

Commercial inactivated vaccines improved the clinical picture of H5N1 in challenged birds.The developed vaccines induced protective antibody titres against HPAIV clade 2.3.4.4b within 4 weeks.The developed vaccines provided full protection against challenge by HPAIV clade 2.3.4.4b.The developed vaccines provided a significant reduction in virus shedding.